DNAPrint Genomics

DNAPrint Genomics Shares Outstanding

The The number of shares of DNAPrint Genomics (DNAG) as of Nov 7, 2026 is 365.24 M.

Shares Outstanding

365.24 M

Last updated:

In 2006, DNAPrint Genomics had 365.24 M outstanding stocks, a % change from the - stocks in the previous year.

The DNAPrint Genomics Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2000
630.33 USD
Jan 1, 2001
20.81 USD
Jan 1, 2002
23.22 USD
Jan 1, 2003
26.15 USD
Jan 1, 2004
42.47 USD
Jan 1, 2005
187.98 USD
Jan 1, 2006
365.24 M USD
The DNAPrint Genomics Shares Outstanding history
YEARShares OutstandingYoY
365.24 M+194.30 M%
187.98+342.59%
42.47+62.40%
26.15+12.62%
23.22+11.59%
20.81-96.70%
630.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DNAPrint Genomics Number of shares

DNAPrint Genomics shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2000
630.33 M Stocks
Jan 1, 2001
20.81 M Stocks
Jan 1, 2002
23.22 M Stocks
Jan 1, 2003
26.15 M Stocks
Jan 1, 2004
42.47 M Stocks
Jan 1, 2005
187.98 M Stocks
Jan 1, 2006
430.41 M Stocks

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating DNAPrint Genomics's Shares Outstanding

DNAPrint Genomics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in DNAPrint Genomics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding DNAPrint Genomics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in DNAPrint Genomics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about DNAPrint Genomics stock

The number of shares of DNAPrint Genomics is 365.24 M in 2006.

On Eulerpool you can find the complete historical development of The number of shares DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics